The Impact of Broad Glutamine Metabolism Inhibition on the Tumor Microenvironment
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Rais R, Lemberg K, Tenora L, Arwood M, Pal A, Alt J
. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Sci Adv. 2022; 8(46):eabq5925.
PMC: 9668306.
DOI: 10.1126/sciadv.abq5925.
View
2.
Oh M, Sun I, Zhao L, Leone R, Sun I, Xu W
. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest. 2020; 130(7):3865-3884.
PMC: 7324212.
DOI: 10.1172/JCI131859.
View
3.
Kaushik A, Tarangelo A, Boroughs L, Ragavan M, Zhang Y, Wu C
. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Sci Adv. 2022; 8(50):eabp8293.
PMC: 9757752.
DOI: 10.1126/sciadv.abp8293.
View
4.
Huang M, Xiong D, Pan J, Zhang Q, Sei S, Shoemaker R
. Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer. Adv Sci (Weinh). 2022; 9(26):e2105885.
PMC: 9475521.
DOI: 10.1002/advs.202105885.
View
5.
Leone R, Zhao L, Englert J, Sun I, Oh M, Sun I
. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019; 366(6468):1013-1021.
PMC: 7023461.
DOI: 10.1126/science.aav2588.
View